CAMP4 Therapeutics Corporation APIC, Share-based Payment Arrangement, Increase for Cost Recognition
CAMP4 Therapeutics Corporation (CAMP) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.93 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- CAMP4 Therapeutics Corporation apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.93M, a 92.71% increase year-over-year.
- CAMP4 Therapeutics Corporation apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.47M, a 70.96% increase year-over-year.
- CAMP4 Therapeutics Corporation apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $984.00K, a 38.19% decline year-over-year.
- CAMP4 Therapeutics Corporation apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.00M, a 27.48% increase year-over-year.
- CAMP4 Therapeutics Corporation apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $4.00M, a 0.84% decline from fiscal 2024.
- CAMP4 Therapeutics Corporation apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $4.03M, a 38.70% increase from fiscal 2023.
- CAMP4 Therapeutics Corporation apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.91M.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.93M 10-Q · filed 2026-08-13 | $3.40M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $1.47M 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $4.00M 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $984.00K 10-Q · filed 2025-11-06 | $1.99M derived: sum of 2 quarters · filed 2026-08-13 | $2.85M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | $1.00M 10-Q · filed 2026-08-13 | $1.86M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $861.00K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $4.03M 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $1.59M 10-Q · filed 2025-11-06 | $2.38M derived: sum of 2 quarters · filed 2025-11-06 | $3.23M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $786.00K 10-Q · filed 2025-11-06 | $1.64M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $856.00K 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $2.91M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $722.00K 10-Q · filed 2024-11-21 | $1.51M derived: sum of 2 quarters · filed 2024-11-21 | $2.27M derived: sum of 3 quarters · filed 2024-11-21 | |
| 2023-06-30 | $786.00K 10-Q · filed 2024-11-21 | $1.55M derived: sum of 2 quarters · filed 2024-11-21 | ||
| 2023-03-31 | $763.00K 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |